Hepatitis C drug prescriptions and Medicaid policies--four states, Indian health care system, USA 2018

Medicaid, the state-level public insurance in the United States, has widely differing criteria treatment for hepatitis C virus (HCV) such as stage of liver fibrosis, documented sobriety, and specialist consultation. In a rural health network, facilities located in two less restrictive states prescri...

Descripción completa

Detalles Bibliográficos
Autores principales: Reilley, Brigg, Miller, Matt, Hudson, Matt, Haverkate, Rick, Leston, Jessica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894296/
https://www.ncbi.nlm.nih.gov/pubmed/31801547
http://dx.doi.org/10.1186/s12939-019-1101-4
_version_ 1783476363374624768
author Reilley, Brigg
Miller, Matt
Hudson, Matt
Haverkate, Rick
Leston, Jessica
author_facet Reilley, Brigg
Miller, Matt
Hudson, Matt
Haverkate, Rick
Leston, Jessica
author_sort Reilley, Brigg
collection PubMed
description Medicaid, the state-level public insurance in the United States, has widely differing criteria treatment for hepatitis C virus (HCV) such as stage of liver fibrosis, documented sobriety, and specialist consultation. In a rural health network, facilities located in two less restrictive states prescribed HCV drugs at a significantly higher rate than two more restrictive states (rate ratio 4.7, CI 2.6–8.5). Prescription rates per population were highly associated with HCV treatment policies.
format Online
Article
Text
id pubmed-6894296
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68942962019-12-11 Hepatitis C drug prescriptions and Medicaid policies--four states, Indian health care system, USA 2018 Reilley, Brigg Miller, Matt Hudson, Matt Haverkate, Rick Leston, Jessica Int J Equity Health Letter to the Editor Medicaid, the state-level public insurance in the United States, has widely differing criteria treatment for hepatitis C virus (HCV) such as stage of liver fibrosis, documented sobriety, and specialist consultation. In a rural health network, facilities located in two less restrictive states prescribed HCV drugs at a significantly higher rate than two more restrictive states (rate ratio 4.7, CI 2.6–8.5). Prescription rates per population were highly associated with HCV treatment policies. BioMed Central 2019-12-04 /pmc/articles/PMC6894296/ /pubmed/31801547 http://dx.doi.org/10.1186/s12939-019-1101-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Reilley, Brigg
Miller, Matt
Hudson, Matt
Haverkate, Rick
Leston, Jessica
Hepatitis C drug prescriptions and Medicaid policies--four states, Indian health care system, USA 2018
title Hepatitis C drug prescriptions and Medicaid policies--four states, Indian health care system, USA 2018
title_full Hepatitis C drug prescriptions and Medicaid policies--four states, Indian health care system, USA 2018
title_fullStr Hepatitis C drug prescriptions and Medicaid policies--four states, Indian health care system, USA 2018
title_full_unstemmed Hepatitis C drug prescriptions and Medicaid policies--four states, Indian health care system, USA 2018
title_short Hepatitis C drug prescriptions and Medicaid policies--four states, Indian health care system, USA 2018
title_sort hepatitis c drug prescriptions and medicaid policies--four states, indian health care system, usa 2018
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894296/
https://www.ncbi.nlm.nih.gov/pubmed/31801547
http://dx.doi.org/10.1186/s12939-019-1101-4
work_keys_str_mv AT reilleybrigg hepatitiscdrugprescriptionsandmedicaidpoliciesfourstatesindianhealthcaresystemusa2018
AT millermatt hepatitiscdrugprescriptionsandmedicaidpoliciesfourstatesindianhealthcaresystemusa2018
AT hudsonmatt hepatitiscdrugprescriptionsandmedicaidpoliciesfourstatesindianhealthcaresystemusa2018
AT haverkaterick hepatitiscdrugprescriptionsandmedicaidpoliciesfourstatesindianhealthcaresystemusa2018
AT lestonjessica hepatitiscdrugprescriptionsandmedicaidpoliciesfourstatesindianhealthcaresystemusa2018

Ejemplares similares